Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2001
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140140A2 Composition and method for improving function of embryonic kidney transplants
10/10/2001EP1140133A1 Controlled release formulation comprising gnrh-ii
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140106A1 Treatment of diseases involving cyst formation
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140095A1 (2-imidazoline-2-ylamino) quinoxaline derivatives for the treatment of pain
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/10/2001EP1140021A1 Improved formulation for topical non-invasive application in vivo
10/10/2001EP1139972A1 Dihydropyrimidines and uses thereof
10/10/2001EP1139753A1 Formulations for treating disease and methods of using same
10/10/2001CN1316993A 4,4-biarylpiperidime derivatives with opioid receptor activity
10/10/2001CN1316906A Stable liquid formulations of botulinum toxin
10/10/2001CN1316258A Natural drug fumigating liquid and its preparing process
10/10/2001CN1316244A Application of tea polyphenol in treating kidney disease
10/10/2001CN1072666C (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
10/10/2001CN1072647C Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
10/09/2001US6300499 α1-adrenergic receptor antagonists
10/09/2001US6300359 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt
10/09/2001US6300335 Urogenital disorders
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6300317 Eukarotic cells, polynucleotide, functional agents, membrane permeability, subcellar localization agents and polynucleotide masking agents
10/09/2001US6300313 Means for treating prostate hypertrophy and prostate cancer
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/04/2001WO2001073032A2 Compositions and methods for the therapy and diagnosis of prostate cancer
10/04/2001WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001072994A2 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072839A2 Human g-protein coupled receptors
10/04/2001WO2001072836A2 G-protein coupled receptors
10/04/2001WO2001072830A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
10/04/2001WO2001072826A2 Oncogenic osteomalacia-related gene 1
10/04/2001WO2001072778A2 Method of identifying inhibitors of tie-2
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072745A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
10/04/2001WO2001072737A1 Triarylimidazole derivatives as cytokine inhibitors
10/04/2001WO2001072730A1 Selective preventives/remedies for progressive lesions after organ damage
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072723A1 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/04/2001WO2001072720A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
10/04/2001WO2001072717A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072705A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072669A2 Therapeutic use of polyhydroxy amine derivates
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease
10/04/2001WO2001072292A2 Vitamin d compounds used to stabilize kidney transplants
10/04/2001WO2001047878A8 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/04/2001WO2001032685A3 Gene expression directed by a super-psa promoter
10/04/2001WO2001021773A3 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same
10/04/2001WO2001016319A3 Compositions and methods for the treatment of immune related diseases
10/04/2001WO2001000244A3 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
10/04/2001US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders
10/04/2001US20010027197 Antiproliverative, -carcinogenic and -tumor agents; mitogenesis-activated protein kinase inhibitors; noncytotoxic; binding with high affinity at the adenosine triphosphate binding site of the kinases
10/04/2001US20010027184 Serine/threonine protein kinase (H-SGK2)
10/04/2001US20010026794 Two heterologous DNA encoding gene products; prolonged half-life
10/04/2001EP1138329A2 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
10/04/2001EP1137667A2 Analogues of glp-1
10/04/2001EP1137666A1 Glp-1 analogues
10/04/2001EP1137661A1 Procollagen c-proteinase inhibitors
10/04/2001EP1137656A1 31 human secreted proteins
10/04/2001EP1137637A1 N-(2-phenyl-4-piperidinylbutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
10/04/2001EP1137423A2 Oral administration of lactobacillus for the treatment and prevention of urogenital infection
10/04/2001EP1137422A2 Use of human prostate cell lines in cancer treatment
10/04/2001EP1137410A1 Novel 4-dedimethy laminotetra cycline derivatives
10/04/2001EP1137408A1 Agent for lowering endothelin levels
10/04/2001EP0975631B1 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands
10/04/2001EP0613465B1 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
10/04/2001DE19947154A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
10/04/2001CA2404662A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001CA2404626A1 Novel piperazine derivatives
10/04/2001CA2404532A1 Method of identifying inhibitors of tie-2
10/04/2001CA2404461A1 Human g-protein coupled receptors
10/04/2001CA2404445A1 Tricyclic protein kinase inhibitors
10/04/2001CA2404411A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001CA2404231A1 Methods of treating diseases with activated protein c
10/04/2001CA2404085A1 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof
10/04/2001CA2403909A1 Compositions and methods for the therapy and diagnosis of prostate cancer
10/04/2001CA2403787A1 Il-8 receptor antagonists
10/04/2001CA2402735A1 Human transcription factors
10/04/2001CA2402187A1 Intracorporeal medicaments comprising halogenated xanthene for photodynamic treatment of disease
10/04/2001CA2401748A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
10/04/2001CA2401242A1 Pharmaceutically active pyrrolidine derivatives
10/04/2001CA2399864A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001CA2374911A1 G-protein coupled receptors
10/03/2001CN1315853A Bioenhanced formulations comprising eprosartan in oral dosage form
10/03/2001CN1315174A Composite medicine for treating renale failure
10/03/2001CN1072220C 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derives as neurokinin receptor antagonists
10/02/2001US6297381 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor, ureas or thioureas substituted by a pyrrole or thiophene
1 ... 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 ... 562